U.S. markets close in 4 hours 27 minutes
  • S&P 500

    4,044.33
    +26.56 (+0.66%)
     
  • Dow 30

    33,820.17
    +103.08 (+0.31%)
     
  • Nasdaq

    11,511.24
    +117.42 (+1.03%)
     
  • Russell 2000

    1,916.38
    +30.66 (+1.63%)
     
  • Crude Oil

    78.81
    +0.91 (+1.17%)
     
  • Gold

    1,942.70
    +3.50 (+0.18%)
     
  • Silver

    23.80
    +0.06 (+0.26%)
     
  • EUR/USD

    1.0868
    +0.0012 (+0.11%)
     
  • 10-Yr Bond

    3.5270
    -0.0240 (-0.68%)
     
  • GBP/USD

    1.2318
    -0.0036 (-0.29%)
     
  • USD/JPY

    130.0720
    -0.2860 (-0.22%)
     
  • BTC-USD

    23,146.79
    -46.25 (-0.20%)
     
  • CMC Crypto 200

    525.06
    +6.27 (+1.21%)
     
  • FTSE 100

    7,773.82
    -11.05 (-0.14%)
     
  • Nikkei 225

    27,327.11
    -106.29 (-0.39%)
     

2 Reasons This Stock Could Outperform in 2023

2 Reasons This Stock Could Outperform in 2023

Biotech giant Gilead Sciences (NASDAQ: GILD) is a member of this elite club, having seen its shares rise by 15% year to date. Let's consider two reasons why Gilead Sciences is worth serious consideration heading into the new year. Gilead Sciences' most important unit by some margin remains its HIV business.